Winship Cancer Institute

Emory University

Atlanta, GA

Accepting patients

Alnuctamab

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials
2 trials are hidden based on your filters. Show All